FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Name: FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Published: 2022
License: Public Domain

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

cholangiocarcinoma colorectal-cancer pancreatic-ductal-adenocarcinoma soft-tissue-sarcoma

pancreatic ductal adenocarcinoma, colorectal cancer, esophageal cancer, melanoma (skin), soft tissue sarcoma, head and neck squamous cell carcinoma, cholangiocarcinoma, radioligand therapy, frontier, pnt6555, 177lu-fap, 68ga-fap

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 882957
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.